Addition and correction

The toxicological assessment of two anti-obesity drugs in C. elegans

Layla Aitlhadj and Stephen R. Stürzenbaum*

Toxicol. Res., 2013, 2, 145–150 (DOI: 10.1039/C2TX20096A ). Amendment published 18th March 2013.

The last sentence on p. 145 should read: The dire need for anti-obesity drugs has led to the approval of two anti-obesity drugs; Lorcaserin (a 5HT2C specific agonist) and Qsymia (a combination of phentermine and topiramate) which have been approved by the FDA in 2012 despite initial rejections of the applications for both drugs in 2010.

The Royal Society of Chemistry apologises for this error and any consequent inconvenience to authors and readers.

Back to article